MYDA Advisors’s Phio Pharmaceuticals PHIO Stock Holding History

MYDA Advisors’s Portfolio PHIO Stock Details PHIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-7	Closed	-$134K	–	183
2018 Q1	$134K	Buy	+7	New	+$161K	0.09%	104

Other funds holding PHIO

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

FAAS

First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

MYDA Advisors's PHIO Position: Q2 2018 in Review

MYDA Advisors sold out of Phio Pharmaceuticals (PHIO) in Q2 2018, closing a stake of 7 shares — an estimated $134K sold.

MYDA Advisors first reported a position in PHIO in Q1 2018 and held it in 1 quarter. The position peaked at $134K in Q1 2018. 10 funds tracked by Wall St. Rank hold PHIO as of Q2 2018.

MYDA Advisors reported no remaining Phio Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
MYDA Advisors sold 7 Phio Pharmaceuticals shares in Q2 2018, an estimated $134K.
MYDA Advisors first reported a position in Phio Pharmaceuticals in Q1 2018 and held it in 1 quarter.
MYDA Advisors's Phio Pharmaceuticals position peaked at $134K in Q1 2018.
10 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q2 2018.

Based on MYDA Advisors's 13F filing for Q2 2018, filed 13 Aug 2018.